- Home
- DWTX vs LIXT Comparison
DWTX vs LIXT Comparison
Compare DWTX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- LIXT
- Stock Information
- Founded
- DWTX 2012
- LIXT 2005
- Country
- DWTX United States
- LIXT United States
- Employees
- DWTX N/A
- LIXT N/A
- Industry
- DWTX
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- DWTX
- LIXT Health Care
- Exchange
- DWTX NYSE
- LIXT Nasdaq
- Market Cap
- DWTX 4.0M
- LIXT 4.2M
- IPO Year
- DWTX N/A
- LIXT N/A
- Fundamental
- Price
- DWTX $2.46
- LIXT $1.58
- Analyst Decision
- DWTX
- LIXT
- Analyst Count
- DWTX 0
- LIXT 0
- Target Price
- DWTX N/A
- LIXT N/A
- AVG Volume (30 Days)
- DWTX 80.6K
- LIXT 1.8M
- Earning Date
- DWTX 11-07-2024
- LIXT 11-12-2024
- Dividend Yield
- DWTX N/A
- LIXT N/A
- EPS Growth
- DWTX N/A
- LIXT N/A
- EPS
- DWTX N/A
- LIXT N/A
- Revenue
- DWTX N/A
- LIXT N/A
- Revenue This Year
- DWTX N/A
- LIXT N/A
- Revenue Next Year
- DWTX N/A
- LIXT N/A
- P/E Ratio
- DWTX N/A
- LIXT N/A
- Revenue Growth
- DWTX N/A
- LIXT N/A
- 52 Week Low
- DWTX $1.62
- LIXT $1.31
- 52 Week High
- DWTX $23.50
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- LIXT 40.08
- Support Level
- DWTX N/A
- LIXT $1.56
- Resistance Level
- DWTX N/A
- LIXT $1.62
- Average True Range (ATR)
- DWTX 0.00
- LIXT 0.17
- MACD
- DWTX 0.00
- LIXT -0.03
- Stochastic Oscillator
- DWTX 0.00
- LIXT 11.46
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.